Bile preparations for colorectal disorders

• US 20070072828A1
• Filed: 09/15/2006
• Published: 03/29/2007
• Est. Priority Date: 07/24/1998
• Status: Abandoned Application

• Current Assignee: Seo Yoo
• Original Assignee: Seo Yoo
• Inventors: Yoo, Seo
• Application Number:
  US11/522,162
• Publication Number:
  US 20070072828A1
• Time in Patent Office: Days
• US Class Current: 514/60
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/718 Starch or degraded starch, e.g. amylose, amylopectin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure relates to methods and compositions to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compositions may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of precipitates or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

Claims

1. A method of protecting a colorectum against adenomatous polyposis coli in a subject comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

9. A method according to claim 1, wherein the composition further comprises a pharmaceutical in a pharmaceutically effective amount.

11. A method according to claim 9, wherein the pharmaceutical is selected from the group consisting of aspirin, methyl salicylate, diflunisal, indomethacin, sulindac, diclofenac, ibuprofen, ketoprofen, naproxen, ketorolac, mefenamic acid, piroxicam, meloxicam, coxibscelecoxib rofecoxib, valdecoxib, parecoxib, etoricoxib, nimesulide. oxaliplatin, leucovorin, irinotecan, cimetidine, salicylic acid, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), paclitaxel, oxaliplatin, 5-fluorouracil, azathioprine, mycophenolate mofetil, cyclosporine, mycophenolic acid, tacrolimus, sirolimus, basiliximab, daclizumab, anti-thymocyte globulin (Rabbit), allopurinol, palonosetron, dolasetron, pamidronate, rasburicase, aprepitant, amifostine, gefitinib, palifermin, granisetron, sargramostim, levothyroxine, dronabinol, pegfilgrastim, interleukin eleven, filgrastim, octreotide, cinacalcet, levothyroxine, Liotrix, dexrazoxane, ondansetron, zoledronic acid, celecoxib, fenoprofen, benorylate, faislamine, amoxiprin, carprofen, flurbiprofen, loxoprofen, tiaprofenic acid, meclofenamic, ketorolac, oxaprozin, etodolac, nabumetone, mesalamine, balsalazide, bevacizumab, alemtuzumab, cetuximab, aldesleukin, ibritumomab tiuxetan, pemetrexed, tositumomab, gemcitabine, imatinib, trastuzumab, altretamine, topotecan, interferon alfa-2b, procarbazine, gemtuzumab ozogamicin, vinorelbine, mitoxantrone, denileukin diftitox, rituximab, erlotinib, bexarotene, arsenic trioxide, bortezomib, tretinoin, doxorubicin, dactinomycin, epirubicin, idarubicin, pentostatin, busulfan, temozolomide, melphalan, chlorambucil, mechlorethamine HC, clofarabine, cytarabine, cladribine, mercaptopurine, thioguanine, capecitabine, bicalutamide, flutamide, anastrozole, exemestane, Fulvestrant, letrozole, estramustine , leuprolide, triptorelin pamoate, histrelin, goserelin, porfimer, rotenone, thenoyltrifluoroacetone (TTFA), antimycin A, myxothiazol or oligomycin dexamethasone, methylprednisolone, hydrocortisone, prednisolone, rotenone, thenoyltrifluoroacetone (TTFA), antimycin A, myxothiazol, oligomycin, valdecoxib, rofecoxib, parecoxib and etoricoxib, atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, simvastatin, rosuvastatin, mevastatin, pitavastatin.

2. A method of extending a life of a subject having adenomatous polyposis coli, said method comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

3. A method of maintaining a total body weight in a subject having adenomatous polyposis coli, said method comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

4. A method of ameliorating or treating at least one symptom of adenomatous polyposis coli in a subject having or at risk of having adenomatous polyposis coli, said method comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

5. A method of reducing recurrence of colorectal adenomas in a colorectum of a subject comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

6. A method of extending a life of a subject having colorectal cancer, said method comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

7. A method of maintaining a total body weight in a subject having colorectal cancer, said method comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

8. A method of ameliorating or treating at least one symptom of colorectal cancer in a subject having or at risk of having colorectal cancer, said method comprising:

administering to the subject a composition comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble dietary carbohydrate that escape digestion and absorption in the small intestine, and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

10. A method according to claim 8, wherein the composition further comprises a pharmaceutical in a pharmaceutically effective amount.

12. A method according to claim 10, wherein the pharmaceutical is selected from the group consisting of aspirin, methyl salicylate, diflunisal, indomethacin, sulindac, diclofenac, ibuprofen, ketoprofen, naproxen, ketorolac, mefenamic acid, piroxicam, meloxicam, coxibscelecoxib rofecoxib, valdecoxib, parecoxib, etoricoxib, nimesulide. oxaliplatin, leucovorin, irinotecan, cimetidine, salicylic acid, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), paclitaxel, oxaliplatin, 5-fluorouracil, azathioprine, mycophenolate mofetil, cyclosporine, mycophenolic acid, tacrolimus, sirolimus, basiliximab, daclizumab, anti-thymocyte globulin (Rabbit), allopurinol, palonosetron, dolasetron, pamidronate, rasburicase, aprepitant, amifostine, gefitinib, palifermin, granisetron, sargramostim, levothyroxine, dronabinol, pegfilgrastim, interleukin eleven, filgrastim, octreotide, cinacalcet, levothyroxine, Liotrix, dexrazoxane, ondansetron, zoledronic acid, celecoxib, fenoprofen, benorylate, faislamine, amoxiprin, carprofen, flurbiprofen, loxoprofen, tiaprofenic acid, meclofenamic, ketorolac, oxaprozin, etodolac, nabumetone, mesalamine, balsalazide, bevacizumab, alemtuzumab, cetuximab, aldesleukin, ibritumomab tiuxetan, pemetrexed, tositumomab, gemcitabine, imatinib, trastuzumab, altretamine, topotecan, interferon alfa-2b, procarbazine, gemtuzumab ozogamicin, vinorelbine, mitoxantrone, denileukin diftitox, rituximab, erlotinib, bexarotene, arsenic trioxide, bortezomib, tretinoin, doxorubicin, dactinomycin, epirubicin, idarubicin, pentostatin, busulfan, temozolomide, melphalan, chlorambucil, mechlorethamine HC, clofarabine, cytarabine, cladribine, mercaptopurine, thioguanine, capecitabine, bicalutamide, flutamide, anastrozole, exemestane, Fulvestrant, letrozole, estramustine, leuprolide, triptorelin pamoate, histrelin, goserelin, porfimer, rotenone, thenoyltrifluoroacetone (TTFA), antimycin A, myxothiazol or oligomycin dexamethasone, methylprednisolone, hydrocortisone, prednisolone, rotenone, thenoyltrifluoroacetone (TTFA), antimycin A, myxothiazol, oligomycin, valdecoxib, rofecoxib, parecoxib and etoricoxib, atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, simvastatin, rosuvastatin, mevastatin, pitavastatin.

13. A method according to claim 8, wherein the composition is comprised in an enema.

14. A method according to claim 8, wherein the composition is comprised in a jelly.

15. A method according to claim 14, wherein the jelly further comprises a thickening agent selected from the group consisting of a water soluble polysaccharide and a synthetic cellulose derivative which swells in water.

16. A method according to claim 14, wherein the mucilage further comprises a thickening agent selected from the group consisting of acacia, chondrus, gelatin, xanthan gum carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.

17. A method according to claim 16, wherein the thickening agent is hydroxyethylcellulose.

18. A method according to claim 8, wherein the composition is comprised in a mucilage.

19. A method according to claim 18, wherein the mucilage further comprises a thickening agent selected from the group consisting of a water soluble polysaccharide and a synthetic cellulose derivative which swells in water.

20. A method according to claim 18, wherein the mucilage further comprises a thickening agent selected from the group consisting of acacia, chondrus, gelatin, xanthan gum carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose.

21. A method according to claim 20, wherein the thickening agent is acacia.

22. A method according to claim 8, wherein a composition is comprised in a solution dosage form.

23. A method according to claim 8, wherein the composition is comprised in a suppository.

24. A method according to claim 8, wherein the subject is a mammal.

25. A method according to claim 8, wherein the subject is a human.

26. A method according to claim 8, wherein the first material is present in therapeutically effective amount.

27. A method according to claim 8, wherein the first material is selected from the group consisting of ursodeoxycholic acid, hyodeoxycholic acid, 7-ketolithocholic acid and sodium salt of ursodeoxycholic acid.

28. A method according to claim 8, wherein the first material is ursodeoxycholic acid or sodium salt of ursodeoxycholic acid.

29. A method according to claim 8, wherein the aqueous soluble starch conversion product is selected from the group consisting of maltodextrin, dextrin, liquid glucose, corn syrup solid, and soluble starch.

30. A method according to claim 8, wherein the aqueous soluble starch conversion product is maltodextrin.

31. A method according to claim 8, wherein the aqueous soluble starch conversion product is corn syrup solid.

32. A method according to claim 8, wherein the aqueous soluble dietary carbohydrate that escapes digestion and absorption in the small intestine is selected from the group consisting of non-digestible oligosaccharides, resistant starch, and non-starch polysaccharides

33. A method according to claim 32, wherein the soluble dietary carbohydrates that escape digestion and absorption in the small intestine is soluble non-starch polysaccharide

34. A method according to claim 8, wherein the soluble dietary carbohydrate that escapes digestion and absorption in the small intestine is selected from the group consisting of digestion resistant maltodextrin (fiber sol-2), guar gum, pectin, locust bean gum, cellulose, b-glucan and psyllium fibres

35. A method according to claim 34, wherein the soluble dietary carbohydrate that escapes digestion and absorption in the small intestine is an aqueous soluble digestion resistant maltodextrin (fibersol-2).

36. A method according to claim 8, wherein the weight ratio of the aqueous soluble starch conversion product to the aqueous soluble dietary carbohydrate that escapes digestion and absorption in the small intestine is 1-99:

99-1.

37. A method according to claim 8, wherein the selected pH range is between about 1 and about 10.

38. A clear aqueous solution comprising:

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and 7-ketolithocholic acid;

(b) a carbohydrate selected from the group consisting of an aqueous soluble starch conversion product, an aqueous soluble digestion resistant maltodextrin (fibersol-2), and combinations thereof; and

(c) water,

wherein the first material and the carbohydrate both remain in solution for all pH values of the solution within a selected range of pH values.

39. A method according to claim 38, wherein the weight ratio of the aqueous soluble starch conversion product to the aqueous soluble digestion resistant maltodextrin (fibersol-2) is 1-99:

99-1.

40. An aqueous solution comprising:

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and a bile acid conjugated with an amine by an amide linkage;

(b) a second material comprising a high molecular weight aqueous soluble starch conversion product; and

(c) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

41. A composition according to claim 40 further comprising an alkali.

42. A composition according to claim 41, wherein the alkali is selected from the group consisting of ammonia, sodium hydroxide, sodium carbonate, potassium hydroxide, potassium carbonate, calcium hydroxide, and calcium carbonate.

43. A composition according to claim 41, wherein the molar ratio of base to bile acid is from about 1.0 to about 1.3.

44. A method of protecting a colorectum against adenomatous polyposis coli in a subject comprising:

administering to the subject a dried form of a primary aqueous solubilized bile acid formulation comprising;

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and, combinations thereof;

(b) a second material selected from the group consisting of an aqueous soluble starch conversion product, a resistant maltodextrin, an aqueous soluble non-starch polysaccharide, and combinations thereof; and

,

(c) a third material selected from aqueous soluble ginseng extract, aqueous soluble red ginseng extract, and combinations thereof.

45. A dried form of a primary aqueous solubilized bile acid formulation comprising:

(a) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof; and

(b) an aqueous soluble starch conversion product;

wherein the first material and the aqueous soluble starch conversion product both remain in solution for all pH values of the solution within a selected range of pH values.